Sodium Propionate Plus Immunotherapy for Advanced Stomach Cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether adding sodium propionate (a natural compound) to standard immunotherapy improves outcomes for patients with advanced stomach cancer that cannot be surgically removed. The goal is to help the immunotherapy work better against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of gastric adenocarcinoma (stomach cancer) by biopsy
- Your cancer cannot be removed by surgery, as determined by your doctor
- You are already receiving or starting anti-PD-1 immunotherapy combined with chemotherapy as your first treatment
- Age 18–79 years old with stable vital signs and good overall health
- No history of allergies, drug abuse, or other active cancers
- Not pregnant or breastfeeding, and not enrolled in another drug trial in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new immunotherapy drug (SHR-1701) combined with standard chemoradiotherapy for people with advanced stomach or esophagus cancer that cannot be surgically removed. The goal is to see if adding this immune treatment helps control the tumor better than standard treatments alone.
This trial tests a combination of three treatments—an immunotherapy drug (sintilimab), a blood-vessel-blocking drug (bevacizumab), and chemotherapy—for advanced stomach cancer that cannot be surgically removed but has elevated AFP levels (a tumor marker). The goal is to shrink the tumor and potentially make it operable.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Gastric Cancer (GC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.